5-bromo-2-[1-[1-(5-propylpyrimidin-2-yl)piperidin-4-yl]ethoxy]-[1,3]thiazolo[5,4-b]pyridine
C20H24BrN5OS — CID 131985338
Data last refreshed: (MolForge compound catalog, from PubChem)
About 5-bromo-2-[1-[1-(5-propylpyrimidin-2-yl)piperidin-4-yl]ethoxy]-[1,3]thiazolo[5,4-b]pyridine
5-bromo-2-[1-[1-(5-propylpyrimidin-2-yl)piperidin-4-yl]ethoxy]-[1,3]thiazolo[5,4-b]pyridine (PubChem CID 131985338) has the molecular formula C20H24BrN5OS and a molecular weight of 462.42 g/mol. Its IUPAC name is 5-bromo-2-[1-[1-(5-propylpyrimidin-2-yl)piperidin-4-yl]ethoxy]-[1,3]thiazolo[5,4-b]pyridine.
Molecular Properties
| Compound Name | 5-bromo-2-[1-[1-(5-propylpyrimidin-2-yl)piperidin-4-yl]ethoxy]-[1,3]thiazolo[5,4-b]pyridine |
|---|---|
| PubChem CID | 131985338 |
| Molecular Formula | C20H24BrN5OS |
| Molecular Weight | 462.42 g/mol |
| Exact Mass | 461.09 |
| IUPAC Name | 5-bromo-2-[1-[1-(5-propylpyrimidin-2-yl)piperidin-4-yl]ethoxy]-[1,3]thiazolo[5,4-b]pyridine |
| SMILES | CCCc1cnc(N2CCC(C(C)Oc3nc4ccc(Br)nc4s3)CC2)nc1 |
| InChI | InChI=1S/C20H24BrN5OS/c1-3-4-14-11-22-19(23-12-14)26-9-7-15(8-10-26)13(2)27-20-24-16-5-6-17(21)25-18(16)28-20/h5-6,11-13,15H,3-4,7-10H2,1-2H3 |
| InChIKey | VCDCXTIOOYNFSA-UHFFFAOYSA-N |
| XLogP | 4.88 |
| TPSA | 64.03 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 28 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 462.42 |
| LogP ≤ 5 | 4.88 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 7 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': '2-halo_pyridine', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 131985338 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.